These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 31086287)
21. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multicenter study. Kari MA; Hallman M; Eronen M; Teramo K; Virtanen M; Koivisto M; Ikonen RS Pediatrics; 1994 May; 93(5):730-6. PubMed ID: 8165070 [TBL] [Abstract][Full Text] [Related]
22. Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Yeh TF; Lin YJ; Hsieh WS; Lin HC; Lin CH; Chen JY; Kao HA; Chien CH Pediatrics; 1997 Oct; 100(4):E3. PubMed ID: 9310536 [TBL] [Abstract][Full Text] [Related]
23. One-year outcome in 232 premature infants with birth weights of 750 to 1249 grams and respiratory distress syndrome randomized to rescue treatment with two doses of synthetic surfactant or air placebo. Canadian Exosurf Neonatal Study Group. Saigal S; Robertson C; Sankaran K; Bingham W; Casiro O; MacMurray B; Whitfield M; Long W J Pediatr; 1995 May; 126(5 Pt 2):S61-7. PubMed ID: 7745513 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of Club Cell 10-kDa Protein (CC10) Levels in Full-Term Infants. Gorji N; Pilon AL; Winn ME; Newsome M; Davis JM Neonatology; 2017; 111(3):247-252. PubMed ID: 27902984 [TBL] [Abstract][Full Text] [Related]
25. Comparison of INSURE method with conventional mechanical ventilation after surfactant administration in preterm infants with respiratory distress syndrome: therapeutic challenge. Nayeri FS; Esmaeilnia Shirvani T; Aminnezhad M; Amini E; Dalili H; Moghimpour Bijani F Acta Med Iran; 2014; 52(8):596-600. PubMed ID: 25149882 [TBL] [Abstract][Full Text] [Related]
26. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Kattwinkel J; Bloom BT; Delmore P; Davis CL; Farrell E; Friss H; Jung AL; King K; Mueller D Pediatrics; 1993 Jul; 92(1):90-8. PubMed ID: 8516091 [TBL] [Abstract][Full Text] [Related]
27. Early Intratracheal Administration of Corticosteroid and Pulmonary Surfactant for Preventing Bronchopulmonary Dysplasia in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Meta-analysis. Zhong YY; Li JC; Liu YL; Zhao XB; Male M; Song DK; Bai Y Curr Med Sci; 2019 Jun; 39(3):493-499. PubMed ID: 31209823 [TBL] [Abstract][Full Text] [Related]
28. Lung recruitment improves the efficacy of intubation-surfactant-extubation treatment for respiratory distress syndrome in preterm neonates, a randomized controlled trial. Yang Y; Yan W; Ruan M; Zhang L; Su J; Deng H; Li M BMC Pediatr; 2022 Jan; 22(1):14. PubMed ID: 34980047 [TBL] [Abstract][Full Text] [Related]
29. One-year follow-up of 66 premature infants weighing 500 to 699 grams treated with a single dose of synthetic surfactant or air placebo at birth: results of a double-blind trial. American Exosurf Neonatal Study Group I. Walther FJ; Mullett M; Schumacher R; Sundell H; Easa D; Long W J Pediatr; 1995 May; 126(5 Pt 2):S13-9. PubMed ID: 7745506 [TBL] [Abstract][Full Text] [Related]
30. Prevention of chronic lung disease (CLD) in premature infants with early dexamethasone therapy. Yeh TF Pediatr Pulmonol Suppl; 1997; 16():35-6. PubMed ID: 9443188 [No Abstract] [Full Text] [Related]
31. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Yeh TF; Lin HC; Chang CH; Wu TS; Su BH; Li TC; Pyati S; Tsai CH Pediatrics; 2008 May; 121(5):e1310-8. PubMed ID: 18426851 [TBL] [Abstract][Full Text] [Related]
32. Outcome at twelve months of adjusted age in very low birth weight infants with lung immaturity: a randomized, placebo-controlled trial of human surfactant. Vaucher YE; Harker L; Merritt TA; Hallman M; Gist K; Bejar R; Heldt GP; Edwards D; Pohjavuori M J Pediatr; 1993 Jan; 122(1):126-32. PubMed ID: 8419599 [TBL] [Abstract][Full Text] [Related]
33. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Davis JM; Parad RB; Michele T; Allred E; Price A; Rosenfeld W; Pediatrics; 2003 Mar; 111(3):469-76. PubMed ID: 12612223 [TBL] [Abstract][Full Text] [Related]
34. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Soll R; Ozek E Cochrane Database Syst Rev; 2009 Jan; (1):CD000141. PubMed ID: 19160177 [TBL] [Abstract][Full Text] [Related]
35. Surfactant use in premature neonates <37 weeks gestation: Experience and outcome at a tertiary care hospital. Khan EA; Hashmey I J Pak Med Assoc; 2015 May; 65(5):486-90. PubMed ID: 26028381 [TBL] [Abstract][Full Text] [Related]
36. Less invasive surfactant administration versus endotracheal surfactant instillation followed by limited peak pressure ventilation in preterm infants with respiratory distress syndrome in China: study protocol for a randomized controlled trial. Zhu J; Bao Y; Du L; Huang H; Lv Q; Jiang Y; Dai Y; Chen Z; Shi J; Shi Y; Yang C; Mei H; Jiang H; Sun Y; Sun X Trials; 2020 Jun; 21(1):516. PubMed ID: 32527290 [TBL] [Abstract][Full Text] [Related]